dd conference booklet2 · understand adme and liability assays, and their impacts on med chem., and...

Opal EventsYour Source For Superior Events

dd_conference booklet2.qxd 6/3/2009 10:22 AM

contents3 Agenda

7 Speaker Biographies

13 Drug Discovery Sponsors

14 Notes

25 Evaluation

27 Save the Date: Drug Discovery Partnership

28 Registration Form

> > > > > > > > > > > > > > > > > > > > >

Drug Discovery: Easing the Chemistry Bottleneck

Opal Events | www.opalevents.org2



Conference Day One: Monday, 8th June 2009

7:30a CONTINENTAL BREAKFAST & REGISTRATION

COMPOUND MANAGEMENT'S ROLE IN ACCELERATING DRUGDISCOVERY● Outline compound management's central role in drug discovery● Discuss key responsibilities of compound management in supporting

medicinal chemistry (i.e. accept and rearray compounds for all assays in assay-ready format; and perform LC/ MS analysis for all med chem..solutions liquid handled)

● Understand ADME and liability assays, and their impacts on med chem.,and ADME)

● Discuss the GNF solution and highlight critical part CM played in PK processing

● Use tracking and automation skills to make discovery processes more efficient

John J. Isbell, Ph.D., Director of Analytical Sciences and DMPK, GenomicsInstitute of the Novartis Research Foundation

8:30a

DEVELOPING A GLOBAL BIOLOGICS REGISTRATION SYSTEM● Defining biological entities and their rules for uniqueness; tracking the

lineage of an entity and the relationships between entities ● Understanding and supporting diverse workflows across projects and sites● Integrating with other Drug Discovery applications ● The Special Interest Group (SIG) model for collaborative development:

Minimising project risks and costs

Joseph M. Cesarone, Ph.D., Principal Research Computer Scientist, ScientificInformatics & Automation, Abbott Laboratories

9:15a

PANEL DISCUSSION: COMPARE WORKFLOW FOR COMPOUNDMANAGEMENT● Identify the bottlenecks in compound processing/ workflow

(HTS compound support/ chemistry supply) ● Understand your customers' needs and deliver compounds in a

timely fashion ● Discuss strategies to ensure turnaround time ● Explore workflow options (workstation vs. integrated system; Lead ID

vs. Lead OP ) ● Review compound management and assay management ● Improve real time lead identification strategies

MODERATOR:Dr. Rodney A. Bednar, Senior Investigator and Chief Drug DiscoveryEngineer, Facility for Automation and Screening Technology (FAST), MerckResearch Laboratories

PANELISTS:Janet Diratsaoglu, Head of Chemical Information and Compound InventoryGroups, Hoffman La Roche Scott D. Mosser, Senior Research Associate and Drug Discovery Manager,Facility for Automation and Screening Technology (FAST), Merck ResearchLaboratoriesDr. Sue Holland-Crimmin, Site Director, Sample Management Technologies,GlaxoSmithKlineDavid Harding, Sales Director, RTS Life Science

10:15a

10:00a MORNING REFRESHMENT AND NETWORKING BREAK

KEY AREA FOR DISCUSSIONThe program is shaped to address key bottlenecks along the drug discovery process. This far-reaching discussion on some of the biggest challenges facedby the industry is designed to highlight technology trends as they emerge.

8:15a CHAIRPERSON'S WELCOME & OPENING REMARKS Melvin Reichman, Ph.D., Director LIMR Chemical Genomics Center (LCGC),Lankenau Institute for Medical Research

CASE STUDY: ITERATIVE RANDOM AND FOCUSED SCREENING: ATHOUGHTFUL APPROACH TO INCREASE HIT RATES● Random screening using a small set of collection (20,000 compounds)that covers entire chemical space of the library ● 3-4 rounds of Iterative focused screening using computational modeling ● Improved hit rates with less resources

Suresh B. Poda, Ph.D., Senior Scientist, Lundbeck Research USA11:15a

12:00p LUNCHEON


agenda> > > > > > > > > > > > > > > > > > > > >



agenda> > > > > > > > > > > > > > > > > > > > >


1:15p CORNING EPIC® SYSTEM: A LABEL-FREE PLATFORM FOR HIGHTHROUGHPUT DRUG DISCOVERYThe Epic System is a novel, label-free detection platform designed for both bio-assay development and for high throughput drug discovery. Based on opticalbiosensor technology, the system provides a high sensitivity label-freedetection platform for measuring both molecular interactions in a biochemicalassay, as well as integrated cellular responses of endogeneous or over-expressed receptors in a cell-based assays. Detection of live cell and timedependent cellular response in a pathway unbiased manner with the Epicsystem may provide previously unattainable biological and pharmacologicalinformation for an integrated drug-stimulated cellular response. The SBS-standard 384 well Epic sensor plate enables the adaptation of the Epic systemto HTS drug discovery.This presentation will introduce the principle of the Epicsystem and highlight its applications in drug discovery.

Topics of the discussion include:● Principle of operation of the Epic System;● Applications of the Epic System for cell-based GPCR screening;● Applications in biochemical binding and functional assays for small

molecule and fragment based drug discovery;● Applications for biologic drug discovery;

Arron S. Xu, Ph.D., Manager, North America Epic® Applications Center, Corning

CASE STUDY ROUNDTABLE: STREAMLINING SAMPLE MANAGEMENTPROCESSPanelists will present case study describing how they utilize lean principalto deliver greater value in one or more of the areas listed below:● Safeguard integrity of compound collections● Deliver compounds to customers in timely fashion● Maintain capacity in response to rising demand● Operate at the highest possible efficiency in resource expenditure

and capital investment

MODERATOR:Edward W. Petrillo, Discovery Performance Strategies LLC

Panelists:John J. Isbell, Ph.D., Director of Analytical Sciences and DMPK, GenomicsInstitute of the Novartis Research FoundationManori Turmel, Principal Scientist, AstraZenecaMarybeth S. Burton, Associate Director, Chemical Technologies, Schering-Plough Research Institute

2:00p

PANEL DISCUSSION: STRATEGIES FOR OPTIMAL SCREENING LIBRARYSIZE TO IMPROVE THE EFFICACY OF DRUG DISCOVERY● Incorporates tractable chemistry to improve drug discovery process● Discuss selection on biologically annotated, IP-rich (novel), rationally

designed, and privileged structure molecules● Explore whether screening library as small as 10,000 compounds is

capable of producing better results

MODERATOR:Rick Hammar, Director, Compound Management, Chemistry and ScreeningServices, ASDI Inc.

PANELISTS:Ricardo Macarrón, EMTM, Ph.D., VP of Sample Management Technologies,GlaxoSmithKlineDave Schultz, Ph.D., Director, Protein Production, Libraries & MolecularScreening Facility, Wistar Scientist, Wistar Institute

3:30p

5:15p COCKTAIL RECEPTION

3:00p AFTERNOON REFRESHMENTS AND NETWORKING BREAK

AUTOMATION FROM COMPOUND STORAGE TO ASSAY DEVELOPMENT● Sample storage and retrieval with the ability to randomly access up to

30,000 samples daily● Produce assay plates in nanoliter volumes on demand for HTS● Minimize delivery time to less than 48 hours● Integrate compound management into drug discovery process with

full support to lead identification and lead optimization

Dalin Nie, Head of Compound Management, AstraZeneca4:30p

Conference Day Two: Tuesday, 9th June 2009

7:30a CONTINENTAL BREAKFAST & REGISTRATION

8:15a CHAIRPERSON'S WELCOME & OPENING REMARKS Melvin Reichman, Ph.D., Director LIMR Chemical Genomics Center (LCGC),Lankenau Institute for Medical Research

PRACTICAL APPLICATIONS OF LEAN THINKING PRINCIPLES INCOMPOUND MANAGEMENT● Identify strategies to overcome the 'bottlenecks' ● Gain buy-in from clients for process change ● Implement workflow to minimize "non-value added" work

Marybeth S. Burton, Associate Director, Chemical Technologies, Schering-Plough Research Institute

1:30p


Opal Events | www.opalevents.org 5

Drug Discovery: Easing the Chemistry Bottleneck June 8-9, 2009

QUANTIGENE: SINGLE AND MULTIPLEX GENE EXPRESSION SOLUTIONSFOR DRUG DISCOVERY AND DEVELOPMENT ● QuantiGene multi-format gene expression technology platform can be

used throughout the drug discovery pipeline from primary- andsecondary screening, through toxicology, biomarker discovery and companion diagnostics.

● QuantiGene bead-based multiplex assay enables a novel approach tocompound screening by plexing both genes and samples directly from cell lysates thereby substantially increasing throughput to a level that gene signatures can be made from primary screens. This assay is rapid,sensitive, and allows high throughput gene expression analysis withoutextensive optimization.

● QuantiGene ViewRNA in situ gene expression technology is capable of measuring single RNA molecules in individual cells.The automation-friendly384 well format has a simple assay workflow that is suitable for high-throughput applications such as phenotypic- or reporter gene screening.

● QuantiGene precisely measures RNA expression directly from cell lysatesand tissue homogenates utilizing a unique reporter signal amplification

system, eliminating variations or errors inherent to extraction, reversetranscription and amplification of target molecules.

● QuantiGene singleplex - and multiplex assay applications includemicroarray validation, compound- and RNAi screening and biomarker analysis from multiple matrices including tissue, blood, and FormalinFixed Paraffin Embedded (FFPE) archived samples.

Dr. Gary McMaster, Chief Scientific Officer, Affymetrix9:30a

NARROWING INTERFACE BETWEEN LEAD DISCOVERY & OPTIMIZATION● Thinking backwards: Drug-like to lead-like and back● On-target structure activity relationships (SAR): It's a wide world of

catalog diversity● Off-target structure liability relationships (SLR): A side effect around

every coronary● Lead exploration to lead development: How many roads to CROss● Project Management: When to hold and when to fold; who makes the call?

MODERATOR:Melvin Reichman, Ph.D., Director LIMR Chemical Genomics Center (LCGC),Lankenau Institute for Medical Research

PANELISTS:Li Tao Zhang, Executive Director, Lead Evaluation and MechanisticBiochemistry, Bristol-Myers SquibbJonathan Usuka, Senior Director of Industry Marketing, Accelrys

8:30a

10:15a MORNING REFRESHMENTS AND NETWORKING BREAK

ADME AND THE CHEMISTRY BOTTLENECK - FROM HTS TOPHARMACOKINETICS● HTS in vitro assays can be important steps in designing out unwanted

pharmaceutical properties● The HTS in vitro models should be linked to more complex in vitro and

in vivo models so as to facilitate simulation and 'prediction'● Higher throughput approaches to target engagement and in vivo PK

properties can speed up candidate selection in later LO phases● The choice of appropriate in vitro or in vivo models should be based

on chemotype and not on one-size-fits-all.

Norman Huebert, Team Leader Discovery ADME, Johnson & Johnson10:30a

COMPUTATIONAL DRUG DISCOVERY: INTEGRATING A COLLABORATIVEDATABASE● Learn about the use of computational models for PXR and other ADME/

Tox properties● Learn how a web-based database can foster collaborations in drug discovery

Sean Ekins, Ph.D., D.Sc., Collaborations Director, Collaborative DrugDiscovery Inc.

11:15a

12:00p LUNCHEON


agenda> > > > > > > > > > > > > > > > > > > > >


6 Opal Events | www.opalevents.org6

TECHNOLOGY ROUNDTABLECase studies presented by table facilitators and attendees will serve as thebasis for discussion at each table. Attendees will be allowed to attend (2)table discussions within this hour to allow for greater information sharing.

TABLE 1: CORNING EPIC® SYSTEM: A LABEL-FREE PLATFORM FOR HIGHTHROUGHPUT DRUG DISCOVERYArron S. Xu, Ph.D., Manager, North America Epic® Applications Center,Corning

TABLE 2: TODAY'S CHALLENGES AND RESPECTIVE SOLUTIONS INCOMPOUND MANAGEMENT SOFTWAREMichael Girardi, President, Titian Software

TABLE 3: THE USE OF ECHO® ADE TECHNOLOGY FOR IMPROVINGCOMPOUND MANAGEMENTMark Lasinski, Senior Director, Global Sales, Labcyte

Table 4: CyBio innovations in liquid handling help drive low volumeand high density screening efforts. A sneak peek into CyBio's futuredevelopmentsIan Hanegraaf, General Manager, CyBio

2:00p

PROVIDING HIGH QUALITY AND EFFICIENT SUPPORT FOR THE DIVERSEANALYTICAL WORK-FLOWS IN PHARMACEUTICAL DISCOVERYIn a pharmaceutical discovery organization, scientists carry out diverse setsof complex assays many of which require their own highly sophisticatedvisual and statistical analyses. Allergan recently instituted a researchanalytics program that has developed certain principles to efficientlysupport these analyses.● There is no substitute for a well-structured data warehouse and data mart ● Identify common requirements and automate them in intuitive ways ● Let scientists focus on science not data handling ● Train scientists with their data

Robert Cain, Manager R&D IS, Allergan1:15p

3:00p AFTERNOON REFRESHMENTS AND NETWORKING BREAK

EXPLORE THE UNIQUE CHALLENGE FACED BY ACADEMIA● Target novelty: Publish or patent ● The NIH Roadmap: Biomedical highway to the future--or bridge tonowhere?● 'Probing' the boundaries between basic and applied research ● 'Re-Purposing: Truly a panacea?● 'Better drugs through better chemistry: Huh?

Melvin Reichman, Ph.D., Director LIMR Chemical Genomics Center (LCGC),Lankenau Institute for Medical Research

3:30p

PANEL DISCUSSION: TEAMING UP TO TAME THE BOTTLENECK:INDUSTRIAL-ACADEMIC INTERACTIONS● 'Pharma-Academic partnerships: Devil (God) is in the details ● 'Changing Pharma-Academia landscape: Grants, contracts and

collaboration ● 'Role of Academia in translational research: Conquering the valley

of death ● 'Role of academic technology transfer offices: Bridging the great divide ● 'Explore opportunities for collaboration between Pharma, academia

and the Government: The time is now

MODERATOR:Dr. Rathnam Chaguturu, Director, High Throughput ScreeningLaboratories, University of Kansas

PANELISTS:Krishna Kodukula, Ph.D., Executive Director, Center for Advanced DrugResearch, SRI InternationalJim Baxendale, Executive Director-KU Center for TechnologyCommercialization, University of KansasWei Zheng, Ph.D., Group Leader, Cellular Signaling Assays, NIH ChemicalGenomics CenterJeff Dodge, Ph.D., Research Fellow, Academic Research Liaison, Eli LillyKatya Tsaioun, Ph.D., President, Scientific Director, ApredicaJia Xu, Ph.D., Director of Operations, Johns Hopkins University School ofMedicine

4:15p

5:15p CLOSING REMARKS AND END OF CONFERENCE

>




speaker biographies> > > > > > > > > > > > > > > > > > > > >

James G. Baxendale MS, MBA, Executive Director, UNIVERSITY OF KANSASJim has worked for over thirty-five years in the Kansas City biomedical community. Currently, he serves as the Executive Director of the KU Centerfor Technology Commercialization with responsibility for the intellectual property of all the University of Kansas campuses. Jim's responsibilitiesinclude the commercialization of faculty research by securing patents, trademarks and copyrights, negotiating licenses, research agreements,confidentiality agreements and material transfer agreements. He also assists the management staff of spin-off companies created from theUniversity of Kansas technologies.

Prior to joining the University of Kansas, Jim was Vice-President of Operations for Regional Media Laboratories. Earlier, he served as their Directorof Research & Development and Supervisor of Quality Control. In addition, Jim has held management positions in hospitals and private clinicallaboratories throughout the Greater Kansas City Area.

Jim holds a Bachelor of Science Degree in Medical Technology, a Master of Science in Microbiology from the University of Missouri-Kansas City, andan MBA from the Rockhurst University Executive Fellows MBA Program.

For the Association of Medical Device Manufacturers, in Washington, D.C., Jim served as a member of the Board of Directors, Secretary andPresident. He was appointed by the Commissioner of the Food and Drug Administration to the Medical Device Good Manufacturing Practices AdvisoryCommittee for a 4-year term. Jim served as Chairman of the Silicon Prairie Technology Association BioScience Network Steering Committee for fouryears, and functioned as a Business Counselor, Instructor and Consultant for the Kauffman Foundation Fast Trac program for a period of 7 years.

Dr. Rodney A. Bednar, Senior Investigator, Group Leader, Chief Drug Discovery Engineer, FACILITY FOR AUTOMATION AND SCREENING TECHNOLOGY(FAST) MERCK RESEARCH LABORATORIES

Dr. Rodney A. Bednar, has worked for Merck & Co., Inc. in their West Point Pennsylvania Research Laboratories for the last 18 years. He is a SeniorInvestigator and the Chief Drug Discovery Engineer and founder of FAST. FAST, an acronym that stands for Facility for Automation and ScreeningTechnology. His group has served to transform the Drug Discovery Process at Merck.

Prior to joining Merck, Rodney enjoyed a successful academic career at the SUNY Stony Brook, where he maintains an adjunct appointment. Whilea Professor in the Department of Pharmacological Sciences and in the Department of Chemistry his laboratory contributed to our understanding ofPerfection in Enzyme Catalysis. Rodney was highly regarded for his training of undergraduate, graduate and postdoctoral students in art of scientificresearch and he supported the Stony Brook Medical Schools as the Pharmacology Course Director for 8 years.

Robert Cain, Manager, ALLERGANRobert Cain is a manager at Allergan where he supports drug discovery teams by managing the research analytics program which provides a researchdata warehouse, various customized applications and user support. He received his Ph.D. at the University of Michigan in 1997 where he studiedNMR of macromolecules. After a two year post-doc and NCSU, he became manager of the Allergan chemistry spectroscopy group in 1999. Overthe next few years his group took over responsibility for the Allergan chemical registration systems and began support discovery by federating variousassay data sources using ISIS technology and Spotfire. The experience gained from these attempts led to the Research Data Warehouse project,which integrates all the major lead discovery databases at Allergan into 3rd Normal form data warehouse and a dimensional data mart. His teamdesigned a custom web reporting tool that feature a novel search tools that allows scientists to intuitively create sophisticated queries and designcustom reports. He will be talking about his team's current emphasis, which is to allow Allergan scientists to use the latest statistical & visualanalytics tools to make the best decisions from their data.

Marybeth Burton, Associate Director, Chemical Technologies, SCHERING-PLOUGH RESEARCH INSTITUTEMarybeth Burton is responsible for management of the collection of proprietary research samples at Schering-Plough Research Institute (SPRI). Ms.Burton's responsibilities include oversight of compound acquisition, compound inventory and request fulfillment, compound collection integrity andenhancement, and chemical reagent tracking. In addition, Ms. Burton manages the selection and implementation of new technologies and datamanagement systems in the compound management area. Ms. Burton holds a B.A. in Biology and an M.S. in Information Science.

Contact information:2015 Galloping Hill RdK-15-4, 4920Kenilworth, NJ [email protected]: 908 740 7359Fax: 908 740 7115





Janet Diratsaoglu, Head of Chemical Information and Compound Inventory Groups, HOFFMAN LA ROCHEJanet Diratsaoglu completed her B.S. degree and M.S. degree in chemistry at the University of Karlsruhe in Germany. She joined Roche Nutley in1989 as an assistant information scientist and became the head of chemical information services in 1994.

In 1997, she was appointed to head the chemical information and the compound inventory management groups in Nutley in support of chemistry,oncology, metabolic diseases and HTS groups in research.

Jeffrey A. Dodge, Research Fellow, LILLY RESEARCH LABORATORIESJeffrey A. Dodge received a BS in Chemistry in 1984 at Eckerd College in St. Petersburg, Florida. In 1989, he completed his PhD at University ofCalifornia, Irvine in the field of molecular recognition. He joined Eli Lilly and Company in 1991 after postdoctoral studies at the University of Texas,Austin. Dr Dodge has extensive expertise in nuclear receptors, particularly in the area of selective estrogen receptor modulators and their applicationto women's health where he has published broadly. He is currently a Research Fellow at Lilly Research Laboratories.

Sean Ekins, Collaborations Director, COLLABORATIVE DRUG DISCOVERY INC.Sean Ekins graduated from the University of Aberdeen; receiving his M.Sc., Ph.D. and D.Sc. He was a postdoctoral fellow at Lilly ResearchLaboratories. He has worked as a senior scientist at Pfizer, Senior Computational Chemist at Lilly Research Laboratories, Associate Director ofComputational Drug Discovery at Concurrent Pharmaceuticals, Inc. and Vice President of Computational Biology at GeneGo. Sean is currently workingwith several early stage companies including Collaborations in Chemistry Inc, Collaborative Drug Discovery Inc. and Arnold Consultancy andTechnology LLC. He is also Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland andAdjunct Professor in the Department of Pharmacology at University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School,Piscataway, NJ. He is on the scientific advisory board for Emiliem Inc., ChemSpider, Assay Depot and the advisory board for Chemical Informatics atIndiana University and editorial boards of the Journal of Pharmacological and Toxicological Methods, Drug Metabolism and Disposition, Drug DiscoveryToday, Pharmaceutical Research, Mutation Research Reviews and the ChemSpider Journal of Chemistry. He has authored or co-authored >130 peerreviewed papers and book chapters as well as edited three books on computational applications in pharmaceutical R&D and computational toxicology.His areas of interest are in vitro and computational ADME/Tox, systems biology, cheminformatics and computer-aided drug discovery.

Rick Hammar, National Sales Manager, Director, Compound Management, Chemistry and Screening Services, ASDI INC.Mr. Hammar joined ASDI Inc. in January 2003 and is responsible for developing ASDI's market depth and breadth in outsourced sample preparationservice contracts. He is considered an expert in outsourcing compound management services. He played a key role in the launch of ASDI's reactiveintermediate provision service business model, signing on 24 major pharmaceutical and biotechnology clients within the first 12 months. His 19years of drug discovery sample preparation experience are essential to identifying viable outsourcing opportunities for potential clients, definingappropriate functional specifications, and liaising between client and ASDI project leaders to continually support the changing needs of research.

Prior to joining ASDI, Mr. Hammar was employed for four years at Tomtec, Inc., a global research instrumentation provider, as the Director of BusinessDevelopment and New Applications. Prior to that, Mr. Hammar worked for 10 years as Manager of the Compound Management and Distribution

Joe Cesarone, Principal Research Computer Scientist, ABBOTT LABORATORIESJoe Cesarone is currently a Principal Research Computer Scientist at Abbott Laboratories, which he joined in 1991. He has 18 years experience inthe design and development of enterprise applications for drug discovery. Areas of focus have included small molecule registration and inventorysystems, gene and target knowledge databases, data mining of sequence databases and text mining of the biomedical literature, as well as theintegration of systems across R&D. Most recently Joe has been the project manager for Abbott's global biologics registration system. He holds aB.S. in Chemistry from the University of Illinois at Urbana-Champaign and a Ph.D. in Organic Chemistry from Northwestern University, where heworked in the laboratory of Richard Silverman.

Dr. Rathnam Chaguturu, Executive Director, UNIVERSITY OF KANSASDr. Rathnam Chaguturu is the Executive Director of the High Throughput Screening laboratory at the University of Kansas (Lawrence, Kansas), andco-ordinates drug discovery activities across all academic campuses within the state of Kansas. He has more than 30 years of experience in newlead discovery and development, executing high throughput screens, and managing hit to lead projects. He joined Rutgers University in 1976 as anAssistant Professor of Biochemistry, and later moved to Dow Chemical Company-Central Research Laboratories as a Project Leader. At Dow, Rathnaminstituted the first principles of chemical library screening for new lead discovery, and developed tools for mining in-house chemical archives.Rathnam joined Sierra Sciences as Director of Drug Discovery in 2006 after a 22-year outstanding career at FMC Corporation where he led discovery research efforts focused on ion channel, receptor, enzyme and cell-based targets, and instrumental in designing the industry-first Zymark roboticscreening platform for new lead discovery. He recently organized a well-received workshop on high throughput screening (HTS) strategies in drug discovery, the first of its kind, in Panama City (Panama) aimed at Latin American scientists interested in drug discovery from natural sources. As arepresentative of FMC, he was one of the founding members of the Society for Biomolecular Sciences. He is currently on the executive board of theMidwest chapter of the Laboratory Robotics Interest Group as Academic Screening Chair. Dr. Chaguturu has authored over 45 research publicationsincluding reviews and book chapters, and holds 11 US patents.




David Harding, Sales and Marketing Director, RTS LIFE SCIENCEHe is a chartered engineer with a degree in Electronic and Control Engineering from the University of Hull, UK. David has worked on a range ofautomation applications, starting at Thorn EMI's Central Research Laboratories, Hayes, UK, where he worked on the automated assembly ofconsumer goods. At RTS he has worked on applications ranging from autonomous nuclear power reactor inspection to automated soup production.For the last 14 years David has focused on automation for life science research applications and, in particular, Sample Management.

Dr. Sue Holland-Crimmin, Site Head and Director of Sample Management Technologies, GSK PHILADELPHIADr Sue Holland-Crimmin is Site Head and Director of Sample Management Technologies at GSK Philadelphia. She is WW leader for Quality Initiativesand coleader of Automation & Technology within GSK SMTech. She has worked in areas of Sample Management, HT Screening and IT during herecareer which has spanned 3 countries and major sites within the GSK operation. She holds a PhD in Biochemistry & Genetics and a BSc inMicrobiology and is a trained Lean Sigma facilitator.

Norman D. Huebert, Ph.D., Team Leader ADME, JOHNSON & JOHNSON PRDDr. Huebert received a B.Sc. (Honours) degree in Biochemistry from the University of Saskatchewan in Saskatoon in 1974. He went on to completehis Doctor of Philosophy in Biological Psychiatry in the Neuropsychiatric Research Unit of the Department of Psychiatry at the same University in 1980.

Following his formal training, he joined the Richardson Merrell Research Centre in Strasbourg, France in 1980 in the Pharmacokinetics Group of theClinical Pharmacology Department. In 1996, Dr. Huebert transferred to the Aventis Research Centre in Bridgewater, NJ where he remained untiljoining 3-Dimensional Pharmaceuticals in 2001 as Director of the Analytical Chemistry and Pharmacokinetics Department.

Dr. Huebert's efforts during his time with Aventis Pharmaceuticals were deployed in the support of Discovery and Development research programsthrough the application of in vitro and in vivo experimentation and the Development of Clinical Candidates through Pharmacokinetic support of clinicaldevelopment programs. His initial interests in bioanalytical methodology and techniques and in vivo pharmacokinetics gradually developed in parallelwith that of the industry to the investigation of in vitro techniques for the rapid prediction of pharmacokinetic parameters and the screening of largenumbers of NCE's as a substitute for in vivo experimentation. He is currently Team Leader for ADME for the US RED site of Johnson and JohnsonPRD and continues his interests in the use of in vitro and in vivo techniques to accelerate the advancement of discovery research programs andtheir successful progression into the formal development process.

Contact information:665 Stockton DriveSuite 104Exton, PA [email protected]

Ricardo Macarron, Ph.D., VP of Sample Management Technologies, GLAXOSMITHKLINEDr. Macarron is Vice-President of WW Sample Management Technologies in GlaxoSmithKline R&D. He recently served as President of the Societyfor Biomolecular Sciences (SBS) (2007-2008) and is Associate Editor of the Journal of Biomolecular Screening. He is the author of more than 50publications on the field of biochemistry, lab automation and biomedical research.

He joined GSK in 1992, and has been working since in positions of growing responsibility within the area of drug discovery (high throughput screening-HTS-, biological assay development and compound management).

In his current position Dr. Macarron leads a group responsible for the storage and distribution of all chemical compounds tested in GSK drugdiscovery efforts. This global department employs 100 scientists located in 4 sites in 3 countries (USA, UK, Spain).

Macarron received both his doctorate in Biochemistry and bachelor's degrees in Biology from the University Complutense of Madrid (Spain). Dr.Macarron also holds a master's degree in Technology Management from University of Pennsylvania.

(Rick Hammar continued...)

Department for Bristol Myers Squibb. He was instrumental in reformatting the existing compound collections to support the advent of HighThroughput Screening at BMS, and later oversaw the centralization of storage and distribution at the Wallingford site, supporting seven domesticand international research facilities and multiple collaborations. He was the project manager for the BMS "Haystack" project, the installation andimplementation of the world's largest Automated Storage and Retrieval System for research samples, and a central piece of a $43 M capital project.

Mr. Hammar has attended the University of Connecticut MBA program and has earned his undergraduate B.S. in American Studies with a minor inbusiness management from Central Connecticut State University.

Contact information:601 Interchange BoulevardNewark, DE 19711

[email protected](T) 302.293.5766(F) 302.266.8296


10




Scott Mosser, Senior Research Associate and Drug Discovery Manager, MERCK RESEARCH LABSMy career has been dedicated to identifying novel, efficacious medicines so people can live long and prosperous lives. My earlier years were spentat the bench manually suspending compounds and producing dose inhibition profiles for tens of thousands of compounds. As technologies becameavailable, I wanted to create a workflow that would incorporate the new emerging technologies and help the bench scientist do their job moreefficiently and accurately. Over the last 10 years I have been involved in building a facility for automation and screening technologies with a goal totransform drug discovery at Merck Research Labs.

The key to this transformation has been the development of lean workflows which enable us to support a steady state pipeline flow of high valuesmall molecules through Lead ID and Lead OP phases of drug discovery. In order to accomplish this fete, we had to assemble a group of top notch,flexible and innovative experts in three core areas: robotic automation, assay informatics and biological screening. It has been my privilege to help buildand manage this team to realize the benefits of using integrated robotic systems, work stations and our laboratory information management system.

Dr. Dalin Nie, Head of Compound Management & Automation, Associate Director of HTS & Global Support, ASTRAZENECA R&DSince joined AstraZeneca in the year 2000, Dalin has successfully defined & implemented the compound management and automation processesand established the compound management and automation capability at Wilmington. He designed, managed, established, and enabled theWilmington Automated Compound Management Facility (ACMF), which is serving multiple research sites in several countries

Dalin has been working in the Drug discovery Automation for over 13 years. He is currently the Chair of the Philadelphia Chapter of the LaboratoryRobotic Interest Group (LRIG).

Edward W. Petrillo, Founder, DISCOVERY PERFORMANCE STRATEGIES, LLCEd Petrillo began his career at BMS working on captopril, the first orally active ACE inhibitor. He advanced seven candidates toward the clinic, andinvented Monopril , which reached $400 million in annual sales. In 1995 he began a career focus on novel technologies for drug discovery. TheBMS team developed a commercially-successful array synthesis reactor and a comprehensive PreClinical Research Information System (PCRIS). AsVice President of New Leads, he oversaw the integration of HTS, compound distribution, combinatorial chemistry, and compound liability profiling.In 2004, Ed was appointed Distinguished Research Fellow, Discovery Technology. He pioneered the application of "Lean Thinking" to improve drugdiscovery productivity. Ed was awarded the Bristol-Myers Squibb Pharmaceutical Research Institute's Ondetti & Cushman Career Achievement Awardin 2005. He retired in 2006 to found Discovery Performance Strategies, LLC, delivering consulting services to pharma and technology clients.

Ed and his wife Joan reside in Pennington, New Jersey and enjoy summers at the nearby Jersey shore. Their children have all pursued careers inscience and engineering- Daniel, chemistry; Laura, medicine, and David, mechanical engineering. For the past 10 years Ed's main pastime has beenmentoring high school students in the FIRST (For Inspiration and Recognition in Science and Technology) Robotics program, a nationwide competitionthat encourages interest in technical careers.

Suresh Poda, Senior Scientist, LUNDBECK RESEARCHSuresh Poda (PhD, biochemistry), is a senior scientist at the HTS Center for Lundbeck Research in Paramus, NJ. After completion of his PhD in 1996,he did his postdoctoral research at University of Michigan, Ann Arbor, MI. In 2000, he started his pharmaceutical career at Astra Zeneca R&D,Montreal as a Scientist. His Joined Lundbeck in 2004, where he started working in the area of compound management and HTS.

Lundbeck focuses on CNS disorders. While the primary targets are GPCRs, the company also focuses on other targets that are involved inneurotransmitter and neuro-inflammatory pathways.

Dr. Mel Reichman, Director, LANKENAU INSTITUTE FOR MEDICAL RESEARCH (LIMR) - CHEMICAL GENOMICS CENTER (LCGC)Dr. Mel Reichman received his Ph.D. in Neuroscience from the University of Rochester under a NRSA Fellowship, and did his postdoctoral studiesas NRSA-NIDA Fellow at the Department of Pharmacology, University of Wisconsin Medical School at Madison. Dr. Reichman has held severalleadership positions directing new leads discovery at leading pharma, including: G.D. Searle/Monsanto, Berlex Biosciences/Schering AG, Ligand

Gary McMaster, Ph.D., Chief Scientific Officer, AFFYMETRIXGary brings more than 25 years of experience in drug discovery research and life science technologies to Affymetrix, holding senior managementpositions at Panomics and a number of leading pharmaceutical companies. Prior to being Chief Scientific Officer at Panomics, Gary was Director ofTarget Discovery at Eli Lilly; responsible for defining and implementing the company's research technologies and systems biology programs, includingthe integration of novel life science technologies for the company's target discovery research. Previously, he was Senior Director of Molecular Biologyfor Parke-Davis and Pfizer, where he oversaw the application of technologies and genomics research for drug discovery. Gary also spent 10 years atCiba-Geigy and Novartis. During his tenure there, he held positions of increasing responsibility including Head of CNS Molecular and Cell Biology andHead of Neurodegenerative Diseases. His leadership experience also includes research management positions at the Max-Planck Institute forImmunology and Hoffman-La Roche Pharmaceuticals. Gary received his doctorate in developmental biology from the Swiss Institute for ExperimentalCancer Research and is an author of more than 50 peer-reviewed scientific publications and numerous world and United States patents.




David C. Schultz, Ph.D., Wistar Scientist, THE WISTAR INSTITUTEDr. Schultz received his Bacheor's of Science in Biochemistry from Albright College and a Master's of Science and Ph. D. in Chemistry from LehighUniversity. His thesis research identified OVCA1/DPH2L1 a candidate tumor suppressor gene within a critical region of the genome that is frequentlydeleted in many carcinomas, including breast and ovarian cancers. During a post-doctoral fellowship at the Wistar Institute, he pioneered studiesthat defined basic mechanisms of transcriptional repression by the vertebrate specific KRAB-zinc finger protein family of trascription factors and therole they have in regulation of chromatin structure and epigenetic control of gene expression. He extended this work as an Assistant Professor inthe Department of Pharmacology at Case Western Reserve University, where he focused on the role KRAB-zfp regulation of transcription in musclesatellite cell differention, mammary gland development and Hematopoietic stem cell biology. He returned to the Wistar Institute as a Senior StaffScientist and Director for the Protein Expression, Libraries, & Molecular Screening Facility, where he has been vital to the development of Wistar'sstrategic effort to develop high-throughput screening and a research program in Chemical Biology and Translational Medicine. He is also a veryactive participant in a multi-institutional program project focused on Epigenetics in Ageing and age related pathologies. He is a broadly trainedscientist in the areas of molecular biology, protein biochemistry, pharmacology, and genetic & epigenetic mechanisms of gene expression. His workin these areas has been published as original articles in Genes & Development, Embo Journal, Cancer Research, and Molecular and Cellular Biology.

Katya Tsaioun, Ph.D., Founder and President, APREDICADr. Tsaioun is founder and President of Apredica. Apredica specializes in rapid preclinical in vitro assessment of the ADME Tox (Absorption,Distribution, Metabolism, Elimination and Toxicity) properties of small-molecule and peptide therapeutics. Under Dr.Tsaioun's leadership Apredicahas grown from 1.5 to 9 FTEs in less than 3 years and now is working with over 60 customer companies world-wide, ranging from academicinstitutions and virtual companies to large multinational pharmaceutical organizations. Apredica has established its reputation as a premiereinnovation-driven drug-discovery contract research organization. 80% of Apredica's staff have Ph.D., and each has over 10 years of discoveryexperience. Apredica provides this expertise as an extension of client companies' R&D.

Prior to founding Apredica, Dr. Tsaioun worked as a Group Leader at Surface Logix, where she built a team and developed a complete in vitro ADMEand in vivo DMPK (drug metabolism and pharmacokinetics) program, which were a central part of the company's technology platform for optimizingand advancing drug leads in CNS and oncology therapeutic areas. Her group developed and validated a number of in vitro assays that becamesecondary screens in lead optimization such as BBB screen. This ADME program was instrumental to the 3 IND submissions which occurred within9 months of establishing the in vitro ADME program.

Prior to Surface Logix, Dr. Tsaioun worked at Mitotix (subsequently merged into GPC Biotech), where she pioneered cell-based assay developmentin the area of angiogenesis (oncology) and infectious disease. She gained expertise in assay validation, transfer to automation, running compound-library screens, and managing hit-to-lead and lead-optimization programs. While at GPC Biotech, Dr. Tsaioun managed the outsourcing of a batteryof in vitro ADME assays and introduced and pioneered the establishment of in-house in vitro ADME capabilities, developing and validating a high-to-medium-throughput ADME assay panel and bringing in house in silico ADME prediction models.

Dr. Tsaioun earned her M.S. degree in solid-state chemistry from the Leningrad Institute of Technology, and her Ph.D. from Tufts University. Her Ph.D.thesis on effects of signal transduction and apoptosis factors in the rat brain was done under direction of Drs. James Sadowski and James Josephin the Neuroscience Laboratory. She completed her academic training in the Neurochemistry Department at the Harvard University Primate Center,working on in vivo and in vitro drug-dependence models with cannabinoid receptor and dopamine transporter systems.

Dr. Tsaioun is active in many local and international professional and business societies such as AAPS, ACS, WEST, HBA, and the MIT Enterpriseforum. She was invited to serve as a judge in the Yale Entrepreneurship Society's 2007 and 2008 business plan competitions. Dr. Tsaioun serveson the Scientific Review Boards of Alzheimer's Drug Discovery Foundation and International Rett Syndrome Foundation. Dr. Tsaioun is regularlyinterviewed by trade publications such as Genetic Engineering News, Drug Discovery Technology, and invited to speak at conferences on the topicsof early toxicity assessment, building productive R&D teams, and entrepreneurship.

Manori Turmel, Principal Scientist, ASTRAZENECAManori Turmel graduated with a BEng in Electrical and Electronic Engineering from the City University in London, UK. She received her PhD in ProcessControl Engineering from the Liverpool John Moors University in UK and completed her Post Doctorate Fellowship at the University of Strathclyde inGlasgow, UK. She joined AstraZeneca Pharmaceuticals in 2001, and is currently a Principal Scientist with the Compound Management andAutomation group in AstraZeneca Discovery in Wilmington. She has played a key role in setting up the AstraZeneca Automated CompoundManagement Facility, and has recently been involved in a number of process improvement activities within the Drug Discovery phase. Her interestsare Compound Management, Lab Automation, System Integration, Project Management and Business Process Analysis, Design & Improvements.She currently holds a Green Belt certification in Lean Six Sigma.

(Dr. Mel Reichman continued...)

Pharmaceuticals, OSI Pharmaceuticals and DuPont Pharma. Dr. Reichman is presently Senior Investigator and Director of the Lankenau Institute forMedical Research-Chemical Genomics Center (LCGC), in Wynnewood, PA (www.LIMR.org). He serves as a reviewer on several NIH 'Roadmap' studysections and is an ad hoc consultant for regional biotech and technology companies. He is presently Director of the Lankenau Institute for MedicalResearch (LIMR)-Chemical Genomics Center (LCGC).





Arron S. Xu, Ph.D., Manager, North America Epic® Applications Center, CORNINGArron received his Ph.D. in physical biochemistry from the Department of Biochemistry, University of Sydney, Australia with Prof. Philip W. Kuchel, in1993. Following his Ph.D., he undertook a postdoctoral fellowship at the Australian Cooperative Research Centre for Molecular Technology from1993 to 1995, and a NIH Fogarty International Visiting Fellowship at the Laboratory of Structural Biology, National Institute of Environmental HealthSciences from 1995 to 1998. This was followed by a research faculty post at the University of North Carolina-Chapel Hill before joining CiphergenBiosystem Inc as a scientist and later as scientific program manager. He is currently the manager of the North America Epic®Applications group,Corning Life Sciences. Arron has worked on several areas of research with focuses on cellular membrane transport by NMR, membrane/ion channelbiosensor by impedance spectroscopy, protein engineering, biodegradable scaffold for liver tissue engineer, clinical biomarker proteomics by massspectrometry, and most recently in assay and applications of Epic®technology. He currently manages a team of application scientists for applicationdevelopment and supports centered around the Corning Epic®technology.

Jia Xu, Ph.D., Operation Director, JOHNS HOPKINS ION CHANNEL CENTER (JHICC)Dr Xu received his Ph.D. in Physiology from the Johns Hopkins University School of Medicine. Prior to joining JHICC, he served as vice president ofresearch and development, and general manager of China operations at AVIVA Biosciences Corporation overseeing new product/service developmentprograms in automated eletrophysiology, cardiac safety screening, and rare cell diagnosis. Prior to that, Dr. Xu was a senior scientist at AuroraBiosciences Corporation, leading assay development projects for major pharmaceutical partners.

Litao Zhang, Executive Director of Lead Evaluation and Mechanistic Biochemistry, Applied Biotechnology, BRISTOL-MYERS SQUIBBLITAO ZHANG is Executive Director of Lead Evaluation and Mechanistic Biochemistry, Applied Biotechnology, Bristol-Myers Squibb, Princeton, NewJersey, USA. She plays a leadership role of drug screening from hit identification to lead optimization and has accumulated more than 10 years ofpharmaceutical industry experience with major pharmaceutical companies such as DuPont, Aventis and Bristol-Myers Squibb. Dr. Zhang is authorof several publications and patents. She received her Ph.D. in Biochemistry from Washington University School of Medicine, Saint Louis,Missouri, USA.

Dr. Wei Zheng, Group Leader, NIH CHEMICAL GENOMICS CENTERDr. Wei Zheng is a group leader at NIH Chemical Genomics Center working on lead discovery and optimization for research probes and drugdevelopment for rare diseases. Prior to NIH, He had worked for 12 years in pharmaceutical companies 12 years including Merck and Amgen. Hehas extensive experience in assay development, high throughput screening and lead optimization. Dr. Zheng received a Ph.D. degree in BiochemicalPharmacology at the State University of New York at Buffalo. He is the Editor-in-Chief of Current Chemical Genetics, a new open access journalfocusing on the technologies and research related to the interface of chemical and biology.

>




sponsors> > > > > > > > > > > > > > > > > > > > >

Opal Events would like to thank its sponsors for their considerate support of Drug Discovery: Easing the Chemistry Bottleneck

■ PANOMICS, recently acquired by Affymetrix, is a life science company that offers a platform of reagents and products that enablethe multiplex measurement of molecular events, such as intracellular pathway analysis, cellsignaling and gene expression profiling, in a quantitative and scalable manner. Panomics hasgrown rapidly on the value of its proprietary branched DNA technology for gene expressionanalysis in cell-based assays, as well as our signal transduction and transcription factor assays.

Executive Sponsor

■ CORNING LIFE SCIENCES is a leading developer, manufacturer and global supplier of scientific laboratory products. For more than100 years, Corning has been the trusted partner of researchers seeking new approaches to increase efficiencies, reducecosts and compress timelines in the drug discovery process. Using our unique expertise in the combined fields of optics,materials science, surfaces, and biology, we provide a full range of innovative solutions that improve productivity and

enable breakthrough discoveries. www.corning.com/lifesciences/

Panel Sponsor

■ APREDICA provides discovery and early preclinical contractresearch services for the evaluationand optimization of ADME-Tox andPharmacokinetic properties of drugcandidates. Apredica maximizes thespeed and efficiency of drug-

discovery programs by providing fast turnaround and scientist-to-scientistcommunications. Apredica's scientists have more than 10 years' drug-discovery experience, and 80% have Ph.D.s, making Apredica an idealpartner for small and mid-sized drug-discovery companies, academic andgovernment groups.

■ AsisCHEM is a global contract research organization thatprovides custom synthesis andmedicinal chemistry services atcompetitive FTE rates. The companyspecializes in research-intensivecollaborations that are led by Ph.D.-

level scientific project managers in the U.S. and carried out by a highlyexperienced group of 30 Ph.D.-level chemists in St. Petersburg, Russia. Thecompany offers the highest level of chemistry expertise, superior customerfocus, exhaustive project management, complete quality control, andrelentless risk management.

■ BIOMICROLAB offers affordable robotic systems, qualitycontrol systems, and productivity toolsprimarily used by life scientists forbenchtop sample and compoundmanagement. BioMicroLab's roboticinstruments are complete systems for:

(1) volume inventory management (2) sorting and weighing of vials and testtubes, and (3) 2D bar code decoding. BioMicroLab's robotic platforms arecompatible with SBS standards to allow integration with HTS orientedlaboratory systems.

■ CHEMDIV, INC. (CHEMDIV) is a global discovery and developmentorganization headquartered in SanDiego, CA, USA with subsidiaries inRussia, business and logisticsoperations around the world. CHEMDIVis a provider of external integrated

discovery and development solutions to pharma and biotech partners.Integrated Discovery outSourceÔ platform offered by CHEMDIV covers thecomplete range of disciplines needed to bring a project in CNS, oncology,inflammation, metabolic and infectious disease area from identification ofa biological target (i.e. protein expression, assay development etc.); toclinical drug candidates (ADME/PK, toxicity studies, efficacy models etc.); todrug development candidate ( Phase I to Phase IV). Visit www.chemdiv.comfor more information.

■ Nearing 20 years of experience CYBIO develops, produces and sellstechnology platforms for drugdiscovery and is an undisputed worldleader in simultaneous pipetting. Byoffering scalable systems forautomated labs, CyBio provides

individual modules that can be fully integrated into complete solutions.CyBio automation is ideal for any procedure where miniaturization andreagent conservation are important and CyBio is currently at the forefrontof nano-liter liquid handling.

In those laboratories where reliability and speed are paramount to theprocess, CyBio instruments enjoy heavy use and represent an excellentreturn on investment. Whether the needs are simultaneous liquid handling,precise imaging, or a walk-away answer for your specific application, CyBiois able to provide elegant and durable instruments and integrations for allareas of HTS, genomics and proteomics.

Exhibitor Sponsors


notes> > > > > > > > > > > > > > > > > > > > >







Opal Events coordinates leading pharmaceutical, healthcareand investment management conferences across the United

States, Europe and South America. These events providedelegates with the necessary information and networking

opportunities to help their business grow in today’scompetitive environment.

about us> > > > > > > > > > > > > > > > >

notes> > > > > > > > > > > > > > > > > > > > >


>




evaluation> > > > > > > > > > > > > > > > > > > > >


Opal Events | www.events.org 27


Opal Events is proud to present our next exciting conference Drug Discovery Partnerships: Academia & IndustrialInteractions. Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs. With key productssuffering patent expiration in coming years, the need for new approaches to accelerate development of newchemical entities to treat severely unmet medical needs is more urgent than ever. This event brings togetherpharmaceutical companies, universities, small biotechnology enterprises, government agencies, for-profit and not-forprofit research institutions to exchange ideas, make connections and discuss opportunities to create an environmentthat will foster pharmaceutical innovation.

If you are interested in sponsorship, exhibiting or speaking opportunities, please contact Kay Ye [email protected] or 212 532-9898, extension 263.

Overcome Your Most Critical Challenges in formingAcademia-Industrial Partnerships:

● 'Understand Specific Requirements Regarding Investigational NewDrug (IND) Application and Approval Process

● 'Maximize the Value and Minimize the Risk by Partnering withthe Right Entity

● 'Hear Insider's Guide to Securing Grant Money for Your Drug Discovery Project

● 'Examine Recent United States Decisions and their Impact onPharmaceutical and Academia Patenting

● 'Improve Speed to Market with Seamless Alignment on Scienceand Technology

● '…and much more

Who Will Attend

Pharmaceuticals, Biotech, Academia, Foundation, TechnologyCompanies, and CROs - Manager/ Director/ VP/ Faculty Advisor of:● External Research Collaboration● Scientific Affairs● Business Development● Partnership/ Alliance Management● Office of Technology Transfer● Academic Screening Facilities● School of Medicine/ Life Sciences/ Pharmacy● Grants Manager● Program Officer● Research & Development

OCTOBER 28-30, 2009 - HYATT REGENCY BOSTON, BOSTON, MA




registration> > > > > > > > > > > > > > > > > > > > >


dd conference booklet2 · understand adme and liability assays, and their impacts on med chem., and...

Documents